Welcome to our dedicated page for INNOVENT BIOLGCS UNSP/ADR news (Ticker: IVBIY), a resource for investors and traders seeking the latest updates and insights on INNOVENT BIOLGCS UNSP/ADR stock.
Innovent Biologics, Inc. (IVBIY) is a renowned biopharmaceutical company specializing in the development, manufacturing, and commercialization of high-quality medicines for various diseases, including oncology, cardiovascular, metabolic, autoimmune, and ophthalmology. The company's recent achievements include the publication of results from the Phase 2 TRUST-I study evaluating taletrectinib, a next-generation ROS1 tyrosine kinase inhibitor, and the development of innovative therapies targeting CLDN18.2/CD3 and PD-1/IL-2 pathways.
Innovent Biologics has established itself as a leader in the biopharmaceutical industry, with a strong focus on empowering patients worldwide with affordable, effective treatments. With a diverse portfolio of products and ongoing clinical trials, the company continues to drive innovation and advance the field of biopharmaceuticals.
Rhea-AI Summary
Innovent Biologics, Inc. (01801:HKEX) announces the acceptance of the New Drug Application (NDA) for IBI351, a KRAS G12C inhibitor, by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China. The NDA has been granted Priority Review designation for the treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring KRAS G12C mutation who have received at least one systemic therapy. The NDA is based on the results from a single-arm registrational Phase 2 clinical study (NCT05005234) and will be presented at the upcoming European Society for Medical Oncology (ESMO) Asia Congress 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Innovent Biologics, Inc. (01801) and AnHeart Therapeutics announce the acceptance of the New Drug Application (NDA) for taletrectinib by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China. Taletrectinib is a next-generation ROS1 tyrosine kinase inhibitor (TKI) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have been previously treated with ROS1 TKIs. The NDA acceptance is based on positive results from the Phase 2 TRUST-I trial (NCT04395677), a multicenter, open-label, single-arm trial that evaluated taletrectinib in Chinese ROS1-positive NSCLC patients. Results from an interim analysis of the TRUST-I trial were presented at the European Lung Cancer Congress (ELCC) 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Innovent Biologics, Inc. (HKEX: 01801) has announced the full results from a Phase 2 clinical trial of mazdutide (IBI362), a GLP-1R and GCGR dual agonist, in Chinese patients with type 2 diabetes. The trial demonstrated robust efficacy in glycemic control and weight reduction, along with multiple cardiometabolic benefits and a favorable safety profile. Mazdutide significantly reduced HbA1c levels, fasting plasma glucose, and body weight, offering a potential novel treatment option for T2D patients. The Phase 3 studies of mazdutide in Chinese T2D patients are currently underway.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Innovent Biologics presents latest data of two ophthalmic bispecific antibodies at the AAO 2023 Annual Meeting. Phase 2 study of IBI302 for neovascular age-related macular degeneration (nAMD) showed noninferior BCVA gains compared to aflibercept. Preliminary signal observed for IBI302 in preventing macular atrophy and fibrosis occurrence. Phase 1 study of IBI324 for diabetic macular edema (DME) demonstrated safety and efficacy. Both drugs showed robust efficacy with no new safety risk signals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Innovent Biologics announces positive results from a Phase 2 clinical study of mazdutide 9 mg in Chinese subjects with obesity. Mazdutide demonstrated significant weight loss efficacy, improved cardiometabolic indicators, and a 73.3% reduction in liver fat content. The study also showed favorable safety and tolerability. Phase 3 study expected to begin by the end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Innovent Biologics announces successful dosing of first patient in Phase 3 clinical study for neovascular age-related macular degeneration (nAMD) treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Innovent Biologics and IASO Bio announce updated long-term follow-up data on BMCA CAR-T therapy for multiple myeloma
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Innovent Biologics announces 2023 interim results and major company updates
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Innovent Biologics, Inc. announces that China's National Medical Products Administration has approved SINTBILO®, a PCSK9 inhibitor, for the treatment of hypercholesterolemia and mixed dyslipidemia. This is Innovent's first drug in the cardiovascular field and its tenth product in its commercial portfolio. The approval is based on three Phase 3 clinical trials, and SINTBILO® has shown significant and sustained LDL-C reduction. The approved dosing regimens provide more individualized choices for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Innovent Biologics, Inc. announced that the preclinical results of IBI363 were published in Nature Cancer. The results showed that α-biased IL-2, a component of IBI363, demonstrated superior anti-tumor efficacy and lower toxicity compared to 'not-α' IL-2. IBI363, a PD-1/IL-2 bispecific antibody fusion protein, is currently in Phase 1 studies to evaluate its safety and preliminary antitumor efficacy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of INNOVENT BIOLGCS UNSP/ADR (IVBIY)?
The current stock price of INNOVENT BIOLGCS UNSP/ADR (IVBIY) is $19.15 as of November 21, 2024.
What is the market cap of INNOVENT BIOLGCS UNSP/ADR (IVBIY)?
The market cap of INNOVENT BIOLGCS UNSP/ADR (IVBIY) is approximately 7.9B.
What is Innovent Biologics, Inc. known for?
Innovent Biologics, Inc. is renowned for its development, manufacturing, and commercialization of high-quality medicines for various diseases, including oncology, cardiovascular, metabolic, autoimmune, and ophthalmology.
What are some recent achievements of Innovent Biologics?
Recent achievements of Innovent Biologics include the publication of results from the Phase 2 TRUST-I study evaluating taletrectinib and the development of innovative therapies targeting CLDN18.2/CD3 and PD-1/IL-2 pathways.
How does Innovent Biologics empower patients worldwide?
Innovent Biologics aims to provide affordable, high-quality biopharmaceuticals to patients worldwide, ensuring access to effective treatments for various diseases.
INNOVENT BIOLGCS UNSP/ADR